ACHILLES Advancing in the CHallenge of Improving Lymphoma and LEukemia Survival
- Coordinator
- Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Spain
- Runs
- 1 December 2025 to 30 November 2029
- Status
- Running
- EU funding
- €4.3m
- Total cost
- —
- Partners
- 33 organisations in 12 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101227725
What the project is doing
In the project's own words, from its summary on CORDIS.
ACHILLES is a Doctoral Network (DN) program designed to train the next generation of leaders in hemato-oncology, with a focus on the development of novel therapeutic solutions for hematological malignancies. The network brings together 14 institutions from 10 EU countries and one associated state, along with partners from the biotechnology and drug discovery sectors, including two European policy leaders in hematology, the European Hematology Association (EHA) and the European School of Hematology (ESH).
Through this collaboration, ACHILLES will train 16 Doctoral Candidates (DCs) to develop essential skills in experimental hemato-oncology, including the design, development, and preclinical validation of innovative therapies. ACHILLES is structured around three key scientific objectives (SOs): (1) creating novel experimental models and analytical methods, (2) exploring the oncogenic mechanisms of hematologic malignancies, and (3) developing and validating new therapies, especially targeted treatments for leukemia and lymphoma.
The program will integrate cutting-edge technologies such as AI, multi-omics, and computational modeling to push the boundaries of current research and therapy development. These innovations will be applied to generate better diagnostic tools, predict treatment responses, and optimize therapeutic strategies. With a patient-centered approach, ACHILLES aims to foster both academic and industrial collaboration, bridging gaps between scientific research and clinical application.
This initiative aligns with the EU's Beating Cancer Plan, with a particular focus on improving survival rates and treatment accessibility, especially in Widening Countries. Through strong academic-industrial partnerships, ACHILLES will help create a sustainable impact on the field of hemato-oncology, advancing research, therapies, and ultimately the health outcomes of leukemia and lymphoma patients worldwide.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Institut De Recerca Contra La Leucemia Josep Carreras | Badalona | Spain | Coordinator |
| Institute of Mathematics and Informatics at the Bulgarian Academy of Science | Sofia | Bulgaria | Participant |
| Eidgenoessische Technische Hochschule Zuerich | Zuerich | Switzerland | Associatedpartner |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Leadership Sculptor GmbH | Baden-Baden | Germany | Associatedpartner |
| Saso Kocevar | Heidelberg | Germany | Associatedpartner |
| Sonja Noss | Wiesbaden | Germany | Associatedpartner |
| Ethniko Idryma Erevnon | Athina | Greece | Participant |
| Panepistimio Dytikis Attikis | Aigaleo | Greece | Associatedpartner |
| Cobiomic Bioscience SL | Cordoba | Spain | Associatedpartner |
| Fundacio Centre De Regulacio Genomica | Barcelona | Spain | Associatedpartner |
| Fundacio Privada per a La Recerca I La Docencia Sant Joan De Deu | Esplugues De Llobregat | Spain | Associatedpartner |
| Fundació Internacional Josep Carreras | Barcelona | Spain | Associatedpartner |
| Institut De Investigacio En Ciencies De La Salut Germans Trias I Pujol | Badalona Barcelona | Spain | Associatedpartner |
| Onechain Immunotherapeutics S.l. | Barcelona | Spain | Participant |
| Scienseed SL | Madrid | Spain | Associatedpartner |
| Universidad Complutense De Madrid | Madrid | Spain | Participant |
| Universitat De Barcelona | Barcelona | Spain | Associatedpartner |
| European School of Haematology | Paris | France | Associatedpartner |
| Universite Paris Cite | Paris | France | Participant |
| Universita' Degli Studi Di Milano-Bicocca | Milano | Italy | Participant |
| European Hematology Association | Den Haag | Netherlands | Associatedpartner |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Stichting Vu | Amsterdam | Netherlands | Associatedpartner |
| I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do Porto | Porto | Portugal | Participant |
| Universidade Do Porto | Porto | Portugal | Associatedpartner |
| Universitatea De Medicina Si Farmacie Iuliu Hatieganu Cluj-Napoca | Cluj-Napoca | Romania | Participant |
| Farmaceutski Fakultet Univerziteta U Beogradu | Belgrade | Serbia | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Lunds Universitet | Lund | Sweden | Associatedpartner |
| Lead Biologics International AB | Lund | Sweden | Participant |
| Pixelgen Technologies AB | Stockholm | Sweden | Associatedpartner |
| Sprint Bioscience AB | Huddinge | Sweden | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS